Goldman Sachs Starts Acadia Pharmaceuticals (ACAD) at Neutral

November 11, 2016 8:06 AM EST
Get Alerts ACAD Hot Sheet
Price: $27.15 +2.53%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade ACAD Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Goldman Sachs initiated coverage on Acadia Pharmaceuticals (NASDAQ: ACAD) with a Neutral rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $29.74 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Goldman Sachs

Add Your Comment